Confronto
DSIP vs. Melanotan II
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
121062-08-6
Peso molecolare
848.81 g/mol
1024.18 g/mol
Emivita
0.1 h
1 h
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
9
di cui sull'uomo
1
5
Effetti registrati
3
4
Contraddizioni aperte
1
1
Eventi avversi documentati
1
6
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and Melanotan II?
- DSIP is classified as "Ricerca (altro)", while Melanotan II is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Melanotan II?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "Studio sull'uomo" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Melanotan II in Germany and the United States?
- Germania: DSIP — Non approvato, Melanotan II — Non approvato. Stati Uniti: DSIP — Non approvato, Melanotan II — Non approvato. These are factual summaries with source and review date on the individual pages.